Fenretinide inhibits obesity and fatty liver disease but induces Smpd3 to increase serum ceramides and worsen atherosclerosis in LDLR-/- mice

Dawn Thompson(University of Aberdeen), Nimesh Mody(University of Aberdeen)
bioRxiv (Cold Spring Harbor Laboratory)
July 22, 2022
10.1101/2022.07.22.500933
Cited by 1

Related Papers

Susceptibility to diet-induced obesity and glucose intolerance in the APP SWE/PSEN1 A246E mouse model of Alzheimer’s disease is associated with increased brain levels of protein tyrosine phosphatase 1B (PTP1B) and retinol-binding protein 4 (RBP4), and basal phosphorylation of S6 ribosomal protein
|Diabetologia|2011|81
Pharmacological inhibition of protein tyrosine phosphatase 1B protects against atherosclerotic plaque formation in the LDLR−/− mouse model of atherosclerosis
|Clinical Science|2017|36
Fenretinide inhibits obesity and fatty liver disease but induces Smpd3 to increase serum ceramides and worsen atherosclerosis in LDLR−/− mice
|Scientific Reports|2023|16
GRK5 regulates endocytosis of FPR2 independent of β-arrestins
|Journal of Biological Chemistry|2024|5
Fenretinide inhibits obesity and fatty liver disease but induces Smpd3 to increase serum ceramides and worsen atherosclerosis in LDLR-/- mice
|Research Square|2022|0